KLRB1 binding agents and methods of use thereof
AssigneeThe Brigham and Women's Hospital, Inc.
InventorSteven A. Greenberg
Life of this patent
Estimating the term…
Abstract
KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and/or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Claims16
An antibody that specifically binds to killer cell lectin-like receptor subfamily B, member 1 (KLRB1), the antibody comprising:
- a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 62, and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 65.
Dependencies are inferred from the claim text.